We focused on two groups of pathology markers: (1) cerebrospinal fluid (CSF) biomarkers indexing AD pathologic changes (i.e., CSF Abeta42/40 and pTau181) since DELCODE is enriched for individuals at risk for AD (see Methods), and (2) measures of brain structure integrity such as hippocampal volume and temporal cortex thickness obtained from MRI scans, as those brain regions are especially vulnerable to AD and age-related pathologic changes (Fjell et al., 2013), and global measures of brain structure and neuronal loss (i.e., total gray matter volume and CSF total tau). Here, MAPT is linked to Alzheimer disease.